ImmunityBio [IBRX] vs Regeneron [REGN] Detailed Stock Comparison

ImmunityBio, Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: ImmunityBio, Inc. wins in 6 metrics, Regeneron Pharmaceuticals, Inc. wins in 13 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric ImmunityBio, Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) -21.58 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio -16.24 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio -1.69 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio 0.86 -4.80 ImmunityBio, Inc.
EV/EBITDA -36.99 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 99.34% 31.41% ImmunityBio, Inc.
Operating Margin (TTM) -168.95% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity 70.34% 14.86% ImmunityBio, Inc.
Return on Assets (TTM) -36.17% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-309.19M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 131.27% 15.66% ImmunityBio, Inc.
Price-to-Sales Ratio (TTM) 73.57 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $8.90B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 78.56 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 99.00% 84.95% ImmunityBio, Inc.
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-0.38 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.06 0.40 ImmunityBio, Inc.
Short % of Float 35.80% 2.55% Regeneron Pharmaceuticals, Inc.

ImmunityBio, Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

IBRX
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
ImmunityBio, Inc.0.42%-0.56%-10.54%-13.15%221.17%252.97%
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
ImmunityBio, Inc.131.27%159.12%-47.05%10.76%-76.80%-76.80%
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%

Performance & Financial Health Analysis: ImmunityBio, Inc. vs Regeneron Pharmaceuticals, Inc.

MetricIBRXREGN
Market Information
Market Cap i$8.46B$80.98B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i15,145,162642,495
90 Day Avg. Volume i21,384,744617,765
Last Close$7.13$614.98
52 Week Range$1.95 - $12.43$503.25 - $821.11
% from 52W High-42.64%-25.10%
All-Time High$45.42 (Feb 22, 2021)$1,211.20 (Aug 26, 2024)
% from All-Time High-84.30%-49.23%
Growth Metrics
Quarterly Revenue Growth4.07%0.03%
Quarterly Earnings Growth4.07%-0.08%
Financial Health
Profit Margin (TTM) i0.99%0.31%
Operating Margin (TTM) i-1.69%0.23%
Return on Equity (TTM) i0.70%0.15%
Debt to Equity (MRQ) i-1.699.51
Cash & Liquidity
Book Value per Share (MRQ)$-0.50$304.65
Cash per Share (MRQ)$0.24$83.86
Operating Cash Flow (TTM) i$-304,936,000$4.98B
Levered Free Cash Flow (TTM) i$-213,356,992$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: ImmunityBio, Inc. vs Regeneron Pharmaceuticals, Inc.

MetricIBRX (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-21.5818.00
Forward P/E i-403.5014.21
PEG Ratio i0.86-4.80
Price to Sales (TTM) i73.575.50
Price to Book (MRQ) i-16.242.45
Market Capitalization
Market Capitalization i$8.46B$80.98B
Enterprise Value i$8.90B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i78.564.95
Enterprise to EBITDA i-36.9916.72
Risk & Other Metrics
Beta i0.060.40
Book Value per Share (MRQ) i$-0.50$304.65

Financial Statements Comparison: ImmunityBio, Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricIBRX (2025)REGN (2025)
Revenue/Sales i113.29M14.34B
Cost of Goods Sold i753,0002.10B
COGS % of Revenue i0.7%14.6%
Gross Profit i112.54M12.24B
Gross Margin i99.3%85.4%
Research & Development i218.56M5.85B
Operating Income (EBIT) i-256.03M3.70B
Operating Margin i-226.0%25.8%
EBITDA i-282.76M5.00B
EBITDA Margin i-249.6%34.8%
Pre-Tax Income i-351.61M5.23B
Pre-Tax Income % of Revenue i-310.4%36.5%
Income Tax i-135,000725.80M
Income Tax % of Revenue i-0.1%5.1%
Net Income (Profit) i-351.47M4.50B
Profit Margin i-310.2%31.4%

Balance Sheet & Liquidity Metrics

MetricIBRX (2025)REGN (2025)
Cash & Equivalents i88.33M3.12B
Total Current Assets i314.88M18.02B
Total Current Assets % of Revenue i277.9%125.7%
Total Current Liabilities i61.75M4.37B
Total Current Liabilities % of Revenue i54.5%30.5%
Long-Term Debt i510.54M2.71B
Long-Term Debt % of Revenue i450.7%18.9%
Total Shareholders Equity i-499.57M31.26B
Retained Earnings i-3.73B35.80B
Retained Earnings % of Revenue i-3,289.5%249.6%
Property, Plant & Equipment i96.27M1.54B

Cash Flow Statement Comparison

MetricIBRX (2025)REGN (2025)
Operating Cash Flow i-261.22M6.30B
Operating Cash Flow % of Revenue i-230.6%43.9%
Capital Expenditures i-3.85M0
Free Cash Flow i-309.19M3.77B
FCF Margin i-272.9%26.3%
Debt Repayment i-28,000N/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricIBRXREGN
Shares Short i135.54M2.55M
Short Ratio i4.934.46
Short % of Float i35.80%2.55%
Shares Outstanding i1.01B105.72M
Float Shares i377.71M98.55M
% Held by Insiders i63.67%1.98%
% Held by Institutions i16.96%91.08%
% Held by Public i19.37%6.94%

Dividend Analysis & Yield Comparison: ImmunityBio, Inc. vs Regeneron Pharmaceuticals, Inc.

MetricIBRXREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026